[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-a-aortic-dissection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-a-aortic-dissection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100604987","phase-4-sivelestat-treatment-for-postoperative-organ-protection-in-type-a-aortic-dissection-100604987",false,"NCT07156656","Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection","Assessment of the Efficacy of Sivelestat Sodium Treatment in Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection (STOP): a Multicenter, Double-blind RCT","STOP","Inclusion Criteria:\n\n1. Age 18-75 years inclusive.\n2. Written informed consent obtained before participation.\n3. Confirmed acute Stanford type A aortic dissection scheduled for surgical repair.\n\nExclusion Criteria:\n\n1. Life expectancy ≤ 48 hours.\n2. Pregnant or lactation.\n3. Severe pre-operative liver dysfunction: Child-Turcotte-Pugh score 10-15.\n4. Severe pre-operative renal dysfunction: acute or chronic kidney injury meeting criteria for renal-replacement therapy.\n5. Confirmed COPD or asthma.\n6. Immunosuppression: long-term or \\> 2 weeks continuous systemic corticosteroids.\n7. Concomitant or anticipated use of immunomodulators (Xue-Bi-Jing injection, thymosin, IVIG).\n8. Medical or psychological condition that would interfere with study participation, assessment, or outcomes.","ALL","18 Years","75 Years",{"count":21,"type":22},236,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","The goal of this multicenter, double-blind, randomized controlled trial is to learn if sivelestat sodium (Siv) can protect the organ function in patients suffered operation for acute type A aortic dissection. The main questions it aims to answer are:\n\n* Can the 3-day-treatment of Siv enlarge the Day-0-to-Day-5 drop in the organ-health score (SOFA score)?\n* Can this treatment significantly shrink the area under the SOFA curve from first dose to Day 5?\n* Can this treatment significantly improve the end of patients in 28 days (clinical outcomes)? Researchers will compare drug Siv to a placebo (a look-alike substance that contains no drug) to see if drug Siv works.\n\nParticipants will:\n\n* Take drug Siv or the placebo through vein continuously for 72 hours\n* Receiving regular intensive care in ICU after the operation",[28,29],"Type A Aortic Dissection","Organ Failure, Multiple",[28,31,32,33],"SOFA","Sivelestat Sodium","Multiple Organ Failure","NOT_YET_RECRUITING","2025-08-27",{"date":37,"type":38},"2025-09-05","ACTUAL",{"date":40,"type":22},"2025-09-01",{"date":42,"type":22},"2028-09-30",{"name":44,"class":45},"Shanghai Zhongshan Hospital","OTHER",6,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100531407","safety-and-efficacy-of-xj-procedure-in-patients-with-acute-type-a-aortic-dissection-surgery-100531407","NCT06199401","Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery","Safety and Efficacy of XJ-Procedure in Patients With Acute Type A Aortic Dissection Surgery (ADVANCED-XJ-Ⅱ): A National, Multi-center, Open-label, Randomized, Controlled, Blinded-end Point Trial","ADVANCED-XJ-Ⅱ","Inclusion Criteria:\n\n* Age 18-70 years;\n* Patients with ATAAD attending the relevant department who have been assessed by a clinician as needing \"Sun's procedure\".\n\nExclusion Criteria:\n\n* Severe aortic root involvement (root diameter \\>45 mm, root tear, severe destruction of the aortic root, combined valve disease);\n* Combined coronary artery disease requiring concomitant coronary revascularization;\n* Prior aortic or cardiac surgery;\n* Preoperative severe malperfusion syndromes such as: severe cerebral complications (acute cerebral infarction, cerebral hemorrhage, coma, etc.); malperfusion of abdominal organs or lower extremities \\>12 h;\n* Preoperative combination of severe single or multiple organ failure;\n* Pregnant women;\n* Refused to sign the informed consent form and refused to participate in this study.","70 Years",{"count":57,"type":22},680,[59],"NA","This is a national, multicenter, open-label, randomized, controlled, endpoint-blinded clinical trial of patients diagnosed with ATAAD and undergoing \"Sun's procedure\" coordinated by the First Affiliated Hospital of Xi'an Jiaotong University, China. Per the protocol, \"Sun's procedure\" combined with \"XJ-Procedure\" in the anastomosis of the aortic root and Sun's procedure combined with regular suturing methods of the aortic root will be compared.",[28,62,63],"Complication of Surgical Procedure","Aortic Diseases",[28,65,66,67],"Aortic Root Reinforcement","Cardiovascular Surgery","Postoperative Complication","RECRUITING","2024-07-10",{"date":71,"type":38},"2024-07-12",{"date":73,"type":38},"2024-01-11",{"date":75,"type":22},"2027-12-01",{"name":77,"class":45},"First Affiliated Hospital Xi'an Jiaotong University",1]